Postmarketing Cardiovascular Ischemia and Torsades de Pointes Monitoring for Pazopanib Using Observational Databases
Phase of Trial: Phase IV
Latest Information Update: 31 Mar 2015
At a glance
- Drugs Pazopanib (Primary) ; Bevacizumab; Sorafenib; Sunitinib
- Indications Renal cell carcinoma
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 26 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 Feb 2013 Planned number of patients (1) as reported by ClinicalTrials.gov.
- 21 Feb 2013 Planned End Date changed from 1 Dec 2012 to 1 Dec 2014 as reported by ClinicalTrials.gov.